Drug intelligence / Profile preview

IgG1Rh113

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IgG1Rh113 is a monoclonal anti-D (anti-RhD) antibody of the IgG1 isotype, developed as a potential alternative to polyclonal anti-D immune globulin. It acts by binding to the Rhesus D antigen on red blood cells, aiming to inhibit Fc receptor-mediated phagocytosis of platelets—a mechanism relevant in autoimmune thrombocytopenic purpura (AITP). Studies indicate that IgG1Rh113 can significantly reduce phagocytosis of opsonized platelets, suggesting potential utility in the treatment of AITP and possibly other conditions where anti-D immunoglobulin is used[1].

Beyond the preview

Go deeper on IgG1Rh113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IgG1Rh113.

Explore the full profile